Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors
NCT02267967
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
81
Enrollment
INDUSTRY
Sponsor class
Conditions
Neuroendocrine Tumors
Interventions
DRUG:
Sulfatinib
Sponsor
Hutchison Medipharma Limited